Merck KGaA Signs Cancer-MS Barter Deal With Japan's Ono
This article was originally published in PharmAsia News
Executive Summary
Why pay cash if you can barter asset rights instead? In a duo of agreements announced Oct. 4, Germany's Merck KGaA licensed worldwide rights ex-Japan, Korea and Taiwan to Ono Pharmaceutical Co. Ltd.'s Phase II MS candidate, ONO-4641, while granting Ono Japanese rights to its own Phase III cancer immunotherapy Stimuvax